key: cord-0701511-xccr8djr
authors: Kevorkian, Jean-Philippe; Lopes, Amanda; Sène, Damien; Riveline, Jean-Pierre; Vandiedonck, Claire; Féron, Florine; Nassarmadji, Kladoum; Mouly, Stéphane; Mauvais-Jarvis, Franck; Gautier, Jean-François; Mégarbane, Bruno
title: Oral corticoid, aspirin, anticoagulant, colchicine, and furosemide to improve the outcome of hospitalized COVID-19 patients - the COCAA-COLA cohort study
date: 2021-02-09
journal: J Infect
DOI: 10.1016/j.jinf.2021.02.008
sha: 3e7c5057622f7e747e94393b5a3023f4972e1545
doc_id: 701511
cord_uid: xccr8djr

nan

Corticosteroids mitigate 28-day all-cause mortality in coronavirus disease-2019 patients requiring oxygen or mechanical ventilation (meta-analysis summary odds ratio (OR), 0.66; 95%-confidence interval (95%IC), [0.53-0.82]; P<0.001); however, mortality remains high (32.7%). 1 In a previous observational cohort study, we established that an early 4-day treatment combining corticosteroid (prednisolone dose equivalent, 1.25mg/kg/24h) and furosemide (80mg/day) was effective in reducing the need for mechanical ventilation and overall mortality (OR, 0.35 [0.11-1.01];

P=0.04) in non-critically ill COVID-19 patients. 2 The GRECCO-19 randomized trial suggested a benefit of colchicine in preventing clinical deterioration in hospitalized non-critically ill COVID-19 patients. 3 Similarly, an observational cohort study reported that salicylate treatment was associated with reduction in intensive care unit (ICU) and mechanical ventilation requirements in hospitalized COVID-19 patients, although in-hospital death was not significantly modified. 4 Moreover, prophylactic or intermediate-dose anticoagulation was highly recommended in hospitalized COVID-19 patients who are at high-risk of venous thromboembolic events (VTE). 5 Specifically, direct oral anticoagulant use was shown to be associated with improved outcome. 6 Based on the data discussed above and the pathophysiology of COVID-19 and its complications, i.e. thrombosis, inflammation and congestion, we hypothesized that a five-drug regimen consisting in a 5-day course of 1mg/kg/day prednisone, 80mg/day furosemide, 75 mg/day salicylate, colchicine (1mg loading dose followed by 0.5mg one hour later then 0.5mg every 8h as recommended to treat acute gout) 7 and direct anti-Xa inhibitor such as rivaroxaban or apixaban would optimally mitigate COVID-19-attributed mortality. To address the effectiveness of this five-drug regimen, we designed an observational cohort study (COrtiCoid-Aspirin-Anticoagulant-Colchicine-LAsix ® , the COCAA-COLA study) including all successive non-critically ill COVID-19 patients requiring >1L/min-oxygen and admitted to our ward between 2020/01/09 and 2020/11/30 (during the second wave in France).

Patients who did not receive this regimen were treated with dexamethasone (6mg once daily for up to 10 days) 8 and low-molecular weight heparin (control group). All patients received standard of care, i.e. oxygen with flow adapted to oximetry, proton pump inhibitor, antibiotics, insulin, potassium supplementation and loperamide if needed. No antiviral or additional immunomodulatory therapy was used due to the absence of clearly demonstrated benefit. Systematic chest computed tomography angiography was performed on admission if not contra-indicated. Anticoagulants (direct anti-Xa inhibitor in the five-drug regimen-treated patients or low-molecular weight heparin in the others) were administered at prophylactic dose with the exception of patients exhibiting VTE or plasma D-dimer ≥5,000ng/mL (a threshold predicting increased VTE risk in COVID-19 patients) 9 who were administered anticoagulants at therapeutic dose. Usual monitoring including pulse oximetry, electrocardiogram, finger blood sugar and daily routine chemical tests was provided.

The primary composite endpoint was requirement of high-flow oxygen therapy, non-invasive or invasive mechanical ventilation (corresponding to care escalation from ward to ICU) or 28-day mortality. The 4C Mortality Score, a risk stratification score for hospitalized COVID-19 patients, was used to predict in-hospital mortality. 10 chronic lung disease, 3%). Twenty-eight patients (41%) received the five drug-therapy regimen whereas forty (59%) were included in the control group. Based on the 4C Mortality Score (10 [8] [9] [10] [11] [12] ), predicted mortality on admission was ~30%. No significant differences were observed between the groups regarding the clinical and biological characteristics and the predicted mortality (Table1).

Noteworthy, 4/40 control patients (10%) at risk of cardiogenic pulmonary edema (serum brain natriuretic peptide (BNP) ≥100ng/mL) received furosemide.

Among patients receiving the five-drug regimen, the incidence of primary composite endpoint was patients receiving colchicine; however, the benefit relied on a narrow margin of clinical significance. 3 By adding colchicine to the recommended corticosteroid and anticoagulant, together with aspirin and furosemide, we succeeded in improving the outcome. The five drugs included in our regimen were given orally for a short course, paving the way for an outpatient treatment. Interestingly, the recent COLCORONA trial conducted in non-hospitalized COVID-19 patients supported colchicine-related benefit in reducing hospitalizations, need for mechanical ventilation and mortality. 11 Colchicine dose regimen differed between the three studies with higher cumulative colchicine doses in the GRECCO-19 (22mg) and COLCORONA trials (16.5mg) compared to ours (8mg). Using the same primary composite endpoint, our five-drug regimen significantly improved prognosis in comparison to the corticosteroid/furosemide combination of our previous study 2 (P=0.0001).

In conclusion, our data highlight the benefit and safety of an early short-course oral regimen combining prednisolone/colchicine/salicylate/direct anti-Xa inhibitor/furosemide to reduce the risk of high flow oxygen need, mechanical ventilation requirement or 28-day mortality in hospitalized non-critically ill COVID-19 patients. Our preliminary observational findings should be confirmed in larger cohorts.

The authors declare that they have no competing interests.

This study was part of the French COVID-19 cohort registry conducted by the REACTing consortium (REsearch and ACTion targeting emerging infectious diseases) and directed by INSERM (Institut national de la santé et de la recherche médicale) and ISARIC (International Severe Acute Respiratory and Emerging Infection Consortium). Our institutional ethics committee approved the study (N°, IDRCB, 2020-A00256-33; CPP, 11-20 20.02.04.68737).

J.-P.K. had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

All the authors agree to publish. in the different patient subgroups defined according to age (using the median value, 66.5 years, as threshold), gender, presence of diabetes mellitus, serum brain natriuretic peptide (BNP; threshold at 100 ng/mL) and troponin levels (threshold at 16 ng/mL). Odds ratio (OR) and their 95%-confidence intervals were determined. 

Evidence Appraisal for COVID-19 Therapies (REACT) Working Group

Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Metaanalysis

Early short-course corticosteroids and furosemide combination to treat non-critically ill COVID-19 patients: An observational cohort study

Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease

Aspirin Use is Associated with Decreased Mechanical Ventilation, ICU Admission, and In-Hospital Mortality in Hospitalized Patients with COVID-19

Impact of oral anticoagulation on clinical outcomes of COVID-19: a nationwide cohort study of hospitalized patients in Germany

Anticoagulation in Hospitalized Patients with Covid-19

updated EULAR evidence-based recommendations for the management of gout

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report

Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System

Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterization Protocol: development and validation of the 4C Mortality Score

Efficacy of Colchicine in Non-Hospitalized Patients with COVID-19